GLP-1 Agonists in dermatology (Glucagon-Like Peptide 1) with Samira Baharlou.

In this episode, we explore one of the most intriguing crossroads in modern medicine: the unexpected territory where metabolic therapy meets the skin.

GLP-1 receptor agonists have transformed the treatment of type 2 diabetes and obesity — but dermatologists are now noticing that these medications may be doing far more than regulating blood sugar and body weight. From inflammatory skin diseases to wound healing, from aesthetic procedures to obesity-related skin conditions, the implications for dermatology are only beginning to unfold.

To make sense of it all, I'm joined by dermatologist Dr. Samira Baharlou. Together, we discuss:

• What the current evidence says about GLP agonists beyond diabetes and obesity, and how the incretin pathway influences inflammation and immunity
• Their potential role in psoriasis, hidradenitis suppurativa, and atopic dermatitis
• The skin-related side effects Belgian dermatologists are already encountering in daily practice
• What we know about wound healing, tissue regeneration, and the risks before and after dermatologic surgery
• How to approach patients on GLP agonists who want laser treatments, fillers, or aesthetic procedures
• Which dermatology patients may benefit most — including those with acanthosis nigricans, lymphedema, or post-bariatric skin issues
• And finally, where the field is heading, with dual and triple agonists already in the research pipeline

A grounded, thoughtful conversation about a rapidly evolving topic — relevant for clinicians, researchers, and anyone curious about how a class of metabolic drugs is starting to reshape dermatology.

Enjoy the episode.